THE SPECIFIC FEATURES OF HEART AND VESSELS REMODELING IN PATIENTS WITH CHRONIC HEART FAILURE TREATED WITH LISINOPRIL DURING 6 MONTHS
https://doi.org/10.20996/1819-6446-2010-6-3-323-328
Abstract
Background. Being able to attenuate pathological remodeling, ACE inhibitors are considered to be first line medications for chronic heart failure (CHF) treatment.
Aim. To study the influence of the 6-month combined therapy with lisinopril on the heart and vessels remodeling in patients with ischemic CHF.
Material and Methods. 40 patients with CHF after Q-myocardial infarction were treated with lisinopril (Listril, Dr.Reddy’s, India) as a part of complex therapy. Initially and after 6 months of therapy the following findings were evaluated: the 6-minute walk test results, echocardiography parameters, main arteries rigidity, endothelium-dependent and independent vasodilatation, anticoagulant and fibrinolytic function of vascular endothelium, von Willebrand factor (VWF).
Results. 6-month treatment with lisinopril showed reduction in CHF functional class in 30 % of patients and increase in left ventricle (LV) stroke volume by 3,8% and LV ejection fraction by 1%. Pulse-wave velocity reduced insignificantly from 10,2 to 9,2 m/sec and augmentation indices of aorta from 31,4% to 29,9% as well as this of brachial artery from -2,6% to -6%. Endothelium-dependent vasodilatation increased from 6,4% to 8,6% and independent vasodilatation – from 13,8% to 16,6%. VWF activity decrease was observed in 40% of CHF patients. Significant changes in anticoagulant and fibrinolytic function of vascular endothelium were not revealed.
Conclusion. Lisinopril administration as a part of complex therapy of CHF patients during 6 months resulted in favorable effect on heart and vessels remodeling and was well tolerated.
About the Authors
N. A. Kosheleva
Saratov State Medical University named after V.I.Razumovsky
Russian Federation
Bolshaya Kazachia ul., 112, Saratov, 410012
Russian Federation
Bolshaya Kazachia ul., 112, Saratov, 410012
A. P. Rebrov
Saratov State Medical University named after V.I.Razumovsky
Russian Federation
Bolshaya Kazachia ul., 112, Saratov, 410012
Russian Federation
Bolshaya Kazachia ul., 112, Saratov, 410012
References
1. Фомин И.В., БеленковЮ.Н., Мареев В.Ю.,Агеев Ф.Т. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации — данные ЭПОХА-ХСН. Сердечная недостаточность 2006; 7(3): 112-115.
2. Мареев В.Ю., Даниелян М.О., Беленков Ю.Н. Сравнительная характеристика больных с ХСН в зависимости от величины фракции выброса по результатам Российского многоцентрового исследования ЭПОХА-О-ХСН. Сердечная недостаточность 2006;7(4):164-171.
3. Garg R., Yusuf S. for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials ofangiotensin-coverting enzyme inhibitors on mortality and morbidity in patients with heart failure JAMA 1995; 273(18): 1450-1456.
4. Thackray S., Witte K., Clark A.L., Cleland J.G. Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail 2000;2(2):209-12.
5. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Сердечная недостаточность 2009; 2: 64-106.
6. КутишенкоН.П.,Марцевич С.Ю.Лизиноприл в кардиологической практике: данные доказательной медицины. Рациональная Фармакотерапия в Кардиологии 2007; 3(5): 1-4.
7. Guyatt G.H., Sullivan M.J., Thompson P.J. et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985; 132(8): 919-923.
8. Lieberman E.H., Gerhard M.D., Uehata A. et al. Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. Am J Cardiol 1996;78(11):1210-4.
9. Williams B., Lacy P.S., Thom S.M. et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principalresults ofthe ConduitArtery Function Evaluation (CAFE) study. Circulation 2006; 113(9):1213-1225.
10. Балуда В.П., Деянов И.И. Значение определения антитромбогенных свойств стенки сосудов в профилактике тромбозов. Кардиология 1988;5:103-104.
11. Blann A.D. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 2006;95(1):49–55.
12. Francis G.S., Benedict C., Johnstone D.E. et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82(5): 1724-9.
13. Skvortsov A.A., Nasonova S.N., Sychev A.V., Baklanova N.A., Mareev V.Yu., Belenkov Yu.N. Effect of long-term treatment with the ACEI quinapril, the angiotensin II type 1 receptor antagonist valsartan
14. and their combination on parameters of left ventricular remodeling in patients with moderate chronic heart failure. Heart Failure 2005; 6(6): 228-233. Russian.
15. Dzau V.J., Hirsch A.T. Emerging role of the tissue renin-angiotensin systems in congestive heart failure. Eur Heart J 1990;11 Suppl B:65-71.
16. Packer M., Poole-Wilson P.A., Armstrong P.W. et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100(23): 2312-8.
17. Solomon S.D., Anavekar N., Skali H. et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005; 112 (24): 3738-3744.
18. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994; 343(8906): 1115-1122.
19. O'Rourke M.F., Staessen J.A., Vlachopoulos C. et al. Clinical applications of arterial stiffness; definitions and reference values. Am J Hypertens 2002; 15(5): 426-444.
20. Орлова Я.А., Агеев Ф.Т. Жесткость артерий как интегральный показатель сердечно-сосудистого риска: физиология, методы оценки и медикаментозной коррекции. Сердце 2006; 5(2): 65-69.
21. Halcox J.P., Schenke W.H., Zalos G. et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002;106(6):653-658.
22. Мареев В.Ю., Балахонова Т.В., Маенко В.П. и др. Влияние квинаприла на клиническое состояние, гемодинамику и эндотелиальную дисфункцию у больных с клинически выраженной ХСН. Сердечная недостаточность 2002; 3(1): 48-49.
23. Endemann D.H., Schiffrin E.L. Endothelial dysfunction. J Am Soc Nephrol 2004;15(8):1983–1992.
24. Балуда В.П., Соколов Е.И., БалудаМ.В. и др. Манжеточная проба в диагностике функционального состояния сосудистого звена системы гемостаза. Гематология и трансфузиология 1987;9:51–53.
25. Felmeden D.C., Spencer C.G., Belgore F.M. et al. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 2003;16(1):11–20.
Review
For citations:
Kosheleva N.A., Rebrov A.P. THE SPECIFIC FEATURES OF HEART AND VESSELS REMODELING IN PATIENTS WITH CHRONIC HEART FAILURE TREATED WITH LISINOPRIL DURING 6 MONTHS. Rational Pharmacotherapy in Cardiology. 2010;6(3):323-328. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-3-323-328
Views:
640
Email this article 